Phase 3 trials
Large randomized trials in people are running or published. It is not a licensed medicine.
This page is a stub
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
How strong is the evidence
How far it has climbed
Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.
- Licensed medicine
A regulator has reviewed the trials and licensed it for a named use.
- Phase 3: Survodutide
Large randomized trials, often thousands of people, against placebo or a standard treatment.
- Phase 2
Mid-sized trials that measure dose against effect in people with the condition.
- Phase 1 and early human studies
First studies in people: safety, and how the body handles it.
- Cells and animals
Laboratory and animal work. An animal result is not a result in people.
- 95
- papers on PubMed
- 58
- of them in people
- 9
- randomized trials
- 52
- reviews
A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16
Handling and reconstitution
From powder to a measured sample
The same four steps for any lyophilized vial. Laboratory handling, not use in a person.
1. Read the vial
The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.
2. Add the diluent
A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.
3. Work out the strength
Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.
4. Measure the sample
Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.
The calculator below does the arithmetic and shows its working.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Survodutide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Survodutide; no amount here is a recommendation.
Survodutide: on PubMed
What PubMed held for Survodutide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 95
- papers
- 58
- in humans
- 10
- clinical trials
- 9
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Randomized trialSanyal AJ, Bedossa P, Fraessdorf M, et al. The New England journal of medicine, 2024. PMID 38847460
- Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis
ReviewSouza M, Al-Sharif L, Antunes VLJ, et al. Hepatology (Baltimore, Md.), 2025. PMID 39903735
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Randomized trialle Roux CW, Steen O, Lucas KJ, et al. The lancet. Diabetes & endocrinology, 2024. PMID 38330987
- Emerging pharmacotherapies for obesity: A systematic review
ReviewKokkorakis M, Chakhtoura M, Rhayem C, et al. Pharmacological reviews, 2025. PMID 39952695
- Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
ReviewSinha B, Ghosal S Obesity (Silver Spring, Md.), 2025. PMID 40685589
- Survodutide Once Weekly for the Treatment of Adults with Obesity
Randomized trialle Roux CW, Wharton S, Startseva E, et al. The New England journal of medicine, 2026. PMID 42253238
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
ReviewDrucker DJ Diabetes care, 2024. PMID 38843460
Search used: ("Survodutide"[tiab]). Run it on PubMed
Research links
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Survodutide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.